Tempest Therapeutics (TPST) Cash from Operations (2012 - 2025)

Tempest Therapeutics has disclosed Cash from Operations across 14 years of filings, most recently posting -$3.6 million for Q4 2025.

• In Q4 2025, Cash from Operations rose 64.78% year-over-year to -$3.6 million; the TTM figure through Dec 2025 stood at -$26.8 million (up 18.79% YoY), while the FY2025 annual figure was -$26.8 million, up 18.79% from the prior year.
• Cash from Operations came in at -$3.6 million for Q4 2025 at Tempest Therapeutics, up from -$6.8 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $127000.0 in Q2 2021 to a low of -$11.8 million in Q3 2021.
• Average Cash from Operations over 5 years is -$7.2 million, with a median of -$7.1 million recorded in 2022.
• Year-over-year, Cash from Operations soared 217.5% in 2021 and sank 6725.2% in 2022.
• Over 5 years, Cash from Operations stood at -$8.0 million in 2021, then climbed by 18.86% to -$6.5 million in 2022, then increased by 4.69% to -$6.2 million in 2023, then sank by 64.36% to -$10.1 million in 2024, then surged by 64.78% to -$3.6 million in 2025.
• Per Business Quant data, the three most recent Cash from Operations figures were -$3.6 million in Q4 2025, -$6.8 million in Q3 2025, and -$8.4 million in Q2 2025.